A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas

Open

Phase

Abbreviated Title

Testing the addition of duvelisib or CC-486 to the usual treatment for peripheral T-cell lymphoma

Status Notes

As of 09/02/2025, A051902 is temporarily closed to accrual, pending a full review of toxicity and tolerability.

Research committees

Lymphoma

Treatment

Cyclophosphamide Prednisone Vincristine Doxorubicin Etoposide

Publication Information Expand/Collapse

2022

A059102: A Randomized Phase II US Intergroup Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas

N Mehta-Shah;N Bartlett;S Barta;J Amengual;S Horwitz;B Kahl;J Friedberg;T Dockter;S Geyer;J Leonard ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), poster session

Other Clinical Trials

SWOG Clinical Trial Number

CTSU/EA4232

A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)

Research Committee(s)

Lymphoma

Activated

01/30/2025

Open

Phase

SWOG Clinical Trial Number

S2308

Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma

Research Committee(s)

Lymphoma

Activated

08/01/2024

Accrual

37%

Open

Phase

SWOG Clinical Trial Number

S2207

Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma

Research Committee(s)

Lymphoma

Activated

06/30/2023

Accrual

14%

Open

Phase